Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.


TSXV:KNE - Post by User

Kane Biotech Inc. > Kane latest presentation (Dec.16th,2020) - Link
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1860)
•••
Comment by lscfaon Dec 30, 2020 7:39pm
118 Views
Post# 32200546

RE:RE:RE:Kane latest presentation (Dec.16th,2020) - Link

RE:RE:RE:Kane latest presentation (Dec.16th,2020) - LinkSo slides 8 and 14 differ. Which is correct?    
StoneMan45 wrote: actually states ..."DispersinB® Wound Care biofilm wash      PMA or BLA 1st Wound Care Bioburden claims        Launching in 2022 2024 Sales projections expected to top $25M USD.."
that is 2024 (not 2025) and at current exchange rates that would be 32 million CND. The projected revenue is specific to the DispersinB Wound Care Biofilm Wash (DispersinB Wound Care Jell). The other products like the Coativ+ Surgical Gel and other DispersinB applications (prosthetic wash and other in development) would all add to this as they become available. 
Kane is an one well run company that is realizing it's potential in a rapid but methodical expansion. Happy to have found this gem



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities